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Abstract 
High titers of anti-citrullinated protein antibodies have been detected in sera of rheumatoid 
arthritis (RA) patients, implicating citrullinating enzymes in the pathogenesis of RA. 
Peptidylarginine deiminase type IV (PAD4) is a member of the PAD family of enzymes that 
catalyze the post- translational modification of arginine to citrulline and has been linked with 
RA. However, little is known about its transcriptional regulation. Therefore, our aim was to 
determine how transcription of PAD4 is activated in the myeloid lineage. Using 
bioinformatics, a potential nuclear factor kappa B (NF-kB) binding site was identified on the 
PAD4 promoter. Luciferase assays were used to test promoter activity in human and murine 
myeloid cells. Interestingly, mutation of the NF-κB binding site significantly lowered 
promoter activity in WEHI-3B cells, but significantly increased it in both HL-60 and THP-1 
cell lines. In addition, PAD4 mRNA was significantly lowered in response to TNF-α 
treatment in HL-60 cells, but increased in WEHI-3B cells. Finally, chromatin 
immunoprecipitation (ChIP) using anti-p50 and anti-p65 antibodies revealed that there was a 
significant increase in p50 enrichment at the PAD4 promoter, but not p65 in cells treated 
with TNF-α. Our results suggest that NF-κB may play an important role in the transcriptional 
regulation of PAD4 in human and murine immune systems. 
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Chapter 1: Introduction 
1.1 Inflammation 
The human body is protected from pathogens and other harmful substances by an arsenal 
of effector cells and molecules that together make up the immune system. In general, the 
immune system carries out four chief tasks in order to protect the individual against 
disease: recognition, effector functions, immune regulation, and immunological memory 
(1). For the most part, the physical and chemical barriers erected by the body against 
pathogens are sufficient to prevent infection. These include antimicrobial proteins 
secreted at mucosal surfaces, as well as innate defenses such as the complement system 
(1, 2). In the event that these barriers are overcome, other components of the innate 
immune system come into action to firstly recognize the foreign agent via detection of 
pathogen associated molecular patterns (PAMPs) and secondly to eliminate the pathogen, 
which occurs via the inflammatory response (3). Inflammation is the process by which 
proteins and cells from the blood are recruited into infected tissues in order to facilitate 
the killing of pathogen. More specifically, inflammation is traditionally described by the 
latin words calor, dolor, rubor, and tumor, meaning heat, pain, redness, and swelling. 
Each of these features reflects an effect of cytokines or other inflammatory mediators on 
local blood vessels. Heat, redness, and swelling result from the dilation and increased 
permeability of blood vessels during inflammation, leading to increased local blood flow 
and leakage of fluid and blood proteins into tissues, whereas pain is accounted for by the 
migration of cells into the tissue and their local actions (Fig. 1.1) (3). The main cell types 
seen in the initial stages of inflammation are macrophages and neutrophils, with  
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Figure 1.1 The acute and resolution phases of inflammation. (A) Illustration of the acute 
phase of inflammation. Polymorphonouclear cells (PMNs) are recruited (among other 
cell types) to the site of infection and extravasate from blood vessels into affected tissue 
(resulting in edema) where they mediate inflammation. (B) Resolution phase. PMN 
infiltration ceases and those PMNs still present in the tissue undergo apoptosis. Adapted 
from Isobe Y et al. (4).  
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neutrophils forming the larger component of the two. Both cell types are the principal 
cells that engulf and destroy the invading microorganisms. Once the pathogen is 
eliminated, the resolution phase of inflammation follows in which various mechanisms 
are enabled to terminate inflammation and prevent damage to healthy tissue surrounding 
the point of infection. Some mechanisms include apoptosis of inflammatory cells (5), 
production and release of interleukin 10 (IL-10) (6), as well as the production of anti-
inflammatory lipoxins (7). If the resolution of inflammation is not achieved correctly, this 
may result in chronic inflammation and continued damage to otherwise healthy tissues of 
the body.  
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1.2 Neutrophils in inflammation 
Neutrophils are important components of innate immunity vital to the maintenance of 
homeostasis of the organism. They are short-lived polymorphonuclear granulocytes 
(PMNs) that form the primary defense against microbial infections. During acute 
inflammation, neutrophils circulating within the bloodstream are rapidly recruited to the 
site of infection (Fig. 1.1) in response to chemotactic factors released by pathogens or 
host cells. After attachment to the endothelium, neutrophils migrate from blood vessels 
and move in line with the chemotactic gradient toward the site of infection. At the site of 
inflammation, activated immune cells acquire the ability to kill pathogens. To carry out 
the killing of bacteria, fungi, and protozoa, neutrophils use a number of strategies such as 
phagocytosis and the recently discovered formation of neutrophil extracellular traps 
(NETs). During phagocytosis, internalized pathogens are translocated to phagosomes 
where the antimicrobial factors derived from granules and reactive oxygen species (ROS) 
create a killing environment for pathogens. However, while the cytotoxic factors 
produced by neutrophils are effective in combating pathogens, they can also be extremely 
damaging to surrounding host tissue if they are not neutralized effectively. The 
engulfment of pathogens by neutrophils is followed by apoptosis, which is a form of 
programmed cell death that ultimately promotes the resolution of inflammation (Fig. 
1.2A). Neutrophils may also combat pathogens by the formation of NETs. During NET 
formation and action (a process termed NETosis), neutrophils extrude networks of 
decondensed chromatin decorated with citrullinated histones and granular antimicrobial 
proteins such as proteinase 3 (PR3), myeloperoxidase (MPO), and α-defensins, among 
others (8).  
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Figure 1.2 Overview of phagocytosis and NETosis. (A) Phagocytosis involves the 
recognition and internalization of pathogens by neutrophils. Following degradation in 
phagosome, neutrophils undergo apoptosis, which promotes resolution of inflammation. 
(B) Upon recognition of some pathogens neutrophils are triggered to release NETs that 
ensnare and kill the pathogen. However, this is accompanied with lysis of the neutrophil 
and release of cyototoxic molecules that may or may not be cleared by the host. Adapted 
from Lu, T et al. (9).  
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NETs act as a mesh that traps microorganisms and facilitates their interaction with 
neutrophil-derived effector molecules, limiting the spread of rapidly disseminating 
pathogens (10). NET formation can be induced by phorbol 12-myristate 13-acetate 
(PMA), lipopolysaccharide (LPS), and bacteria (10). In particular, NETs have been 
shown to trap and kill pathogenic bacteria such as Shigella flexneri (10) and 
Streptococcus pyogenes (11). Moreover, NETs can induce the production of 
antimicrobial cytokines such as interferon-α (IFN-α) (12-14), a relevant cytokine in the 
control of viral, bacterial, and protozoal infections (15).  
Since NETosis fundamentally involves the extracellular exposure of intracellular 
components (Fig. 1.2B), the discovery of NETs has sparked renewed interest in potential 
links between neutrophils and autoimmune disease. For example, the neutrophils of 
systemic lupus erythematosus (SLE) patients have been demonstrated to be more likely to 
form NETs (16), a finding that correlates with increased levels of circulating DNA in the 
plasma of SLE patients as well as the presence of antibodies towards other proteins 
released in NETs (17). Indeed, 74% of NET proteins have been reported to autoantigens 
in several systemic autoimmune diseases, notable among which are SLE, rheumatoid 
arthritis, and vasculitis (18). Thus, while NET formation has been revealed to be a unique 
effector mechanism of neutrophils against pathogens, it raises new questions and opens 
new doors into the study of the origin and pathogenesis of systemic autoimmune diseases. 
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1.3 Autoimmune disease 
Although the main function of the immune system is to protect the human host from 
pathogenic agents, autoimmune diseases result when immune responses are directed at 
self antigens in the absence of any pathogen (19). These immune responses resemble 
normal immune responses in that they are specifically directed towards antigens, in this 
case self antigens or autoantigens, and give rise to autoreactive effector cells and to 
antibodies called autoantibodies against self antigens. Autoimmune diseases can broadly 
be categorized as organ specific (ex. diabetes and multiple sclerosis) in which cases the 
immune system targets autoantigens specific to particular organs, or systemic (ex. 
rheumatoid arthritis) in which cases the inflammation ensues in multiple tissues because 
the autoantigens causing the response are found in several (if not all) tissues of the body. 
In turn, a hallmark feature of systemic autoimmune diseases is the circulation of 
autoantibodies that recognize intracellular antigens thought to be expressed by all cells, 
yet are associated with specific disease phenotypes and outcomes. Since fundamentally 
autoimmune diseases occur because of a failure of the immune system to distinguish self 
from non-self correctly, several factors – both genetic and environmental – are implicated 
in their development. Genetic factors include genes important in the recognition of 
antigen such as those coding for immunoglobulins, T-cell receptors, as well as the major 
histocompatibility complex (MHC) (1). In particular, various MHC II allotypes have 
been associated with specific diseases; for instance, HLA DR2 is associated mostly with 
multiple sclerosis (20) whereas HLA DR4 shows high association with rheumatoid 
arthritis (21).  
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1.4 Rheumatoid arthritis 
Rheumatoid Arthritis (RA) is a chronic, systemic autoimmune disease characterized by 
inflammation and progressive destruction of synovial joints (22). The most common form 
of inflammatory arthritis, RA affects nearly 1% of the world’s population (23). Patients 
suffering from RA will present with a variety of symptoms ranging from mild pain and 
swelling in peripheral joints to widespread inflammation and joint destruction caused by 
a “runaway” immune response involving the development of autoantibodies and resulting 
in significant morbidity and mortality (23, 24).  
Although RA etiology remains unclear, several factors – both genetic and environmental 
– have been associated with disease incidence, and it is thought that genetic 
predisposition to immune system dysregulation, coupled with an infectious event or the 
development of autoantibodies, may be at the center of the autoimmune responses (24). 
Genetic predisposition to RA is supported by twin studies in which higher concordance 
rates of disease were observed among monozygotic twins than dizygotic twins, as well as 
by sibling studies that show a 2-17% increase in the risk of RA contraction among 
siblings than the general population (25). The gene considered to be the major 
determinant of RA susceptibility (accounting for up to 30% of disease susceptibility) is 
human leukocyte antigen (HLA), HLA-DRB1 (25, 26). One of the most polymorphic 
genes in the human genome, HLA-DRB1 encodes the β-chain of the MHC class II 
protein. Several subtypes of the gene (termed shared epitopes) have been associated with 
RA in different populations around the world (25). However, while HLA-DRB1 was 
thought to be the only RA susceptibility gene for nearly three decades, the last ten years 
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have seen the discovery of nearly 30 new RA susceptibility genes (22). Other genetic risk 
factors that have since been identified include the genes coding peptidylarginine 
deiminase type IV (PAD4), protein tyrosine phosphatase non-receptor type 22 (PTPN22), 
signal transducer and activator of transcription (STAT4) as well as several others (22).  
Several environmental factors have been proposed as “triggers” for genetically 
susceptible individuals to develop RA. Among the most well known of these is smoking. 
Beginning in the 1980s, studies emerged demonstrating a higher incidence of RA in 
smokers (27). Furthermore, a positive correlation was found between smoking and 
seropositivity for rheumatoid factor (RF), the previous gold standard for rheumatoid 
arthritis (28, 29). More recently, it was demonstrated that smoking enhances the risk of 
RA in patients expressing anti-citrullinated protein antibodies (ACPAs) – the newly 
established gold standard for detecting and diagnosing RA (see below; (21)). Indeed, 
smoking was shown to enhance the risk of RA only in those individuals expressing 
ACPAs, and had no effect on individuals not expressing ACPAs (21) – an effect that has 
since been demonstrated in European as well as South American populations (30-32). 
Although the exact mechanism of how cigarette smoking contributes to RA, inhaled 
particulate matter (such as that from cigarette smoking) has been shown to trigger 
translocation of the transcription factor NF-κB (33) and may thus initiate pro-
inflammatory cytokine expression contributing to RA.  
Another environmental factor linked to the pathogenesis of RA is exposure to the 
bacterium Porphyromonas gingivalis and its associated infection periodontitis. 
Periodontitis has been demonstrated to increase the risk of RA in non-smokers and is also 
associated with ACPA production (34). Intriguingly, the bacterium is proposed to be able 
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to do this because it expresses a peptidylarginine deiminase (PAD) gene, and it has been 
demonstrated that its ability to express a fully functioning PAD protein – which produces 
citrullinated proteins – is responsible for its facilitation of ACPA driven RA development 
(35). P. gingivalis is the only bacterium known to express PAD, and its own enzyme is 
able to citrullinate both host and bacterial peptides (34). Indeed, ACPAs to the protein 
CEP-1 have been shown to bind the corresponding region of P. gingivalis enolase, 
indicating that microbial mimicry may play a role in the etiopathology of RA (34).  
1.5 Transcriptional regulation 
The proteins a cell produces are a result of each protein’s mRNA levels, the frequency at 
which the mRNA is translated, as well as the stability of the protein itself. The start point, 
however, is the first process of the Central Dogma: the transcription of DNA into RNA – 
the first step towards gene expression. Although there are several steps at which the 
process of gene expression can be regulated to give rise to differential gene expression 
(and the resultant differences in cell properties and functions), it is the first step – 
transcription – which is the most important mechanism in for determining whether or not 
most genes are expressed and how much of the encoded mRNAs are produced (36, 37). 
The proteomic character of a cell is thus determined by which genes are transcribed and 
their rate of transcription in the given cell type. Therefore, it is the differential 
transcription of different genes that largely determines the actions and properties of cells.  
Regulation of gene expression via transcriptional regulation is of paramount importance 
because it affects the execution of precise biological processes such as development, 
proliferation, inflammation, apoptosis, aging, and differentiation. Transcriptional 
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regulation of genes is achieved through the collective action of various cis-regulatory 
elements that are located proximally to genes. These elements include core promoters and 
promoter-proximal elements – located close to the transcription start site (TSS) – as well 
as other elements that are located distantly from the TSS including enhancers, silencers, 
insulators, and tethering elements (Fig. 1.3; (36, 38)). Gene promoters are particularly 
important since they are immediately adjacent to TSSs and are the sites that position the 
transcription initiation complex (PIC) consisting of RNA polymerase and other proteins 
(38). In eukaryotes, RNA polymerase II (RNAPII) is responsible for transcribing all 
protein coding genes – that is, it is responsible for the production of mRNA (38). Since 
this responsibility includes such a hugely diverse array of genes, RNAPII is itself 
controlled in many different ways, with one of these being differing classes of RNAPII 
promoters (38).  
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Figure 1.3 A typical gene regulatory region. The promoter spans an area typically less 
than 1 kb pairs and is composed of a core promoter and proximal promoter elements. 
Distal (upstream) regulatory elements can be located up to 1 Mb pairs from the promoter 
and may include enhancers, silencers, and insulators. Adapted from Maston et al. (37).  
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Another important aspect of the process of transcriptional regulation is the integration of 
several protein signals that culminates in the recruitment of RNAPII and the initiation of 
transcription. Chief among these protein signals is the binding of sequence-specific 
transcription factors (TFs) at their respective transcription factor binding sites (TFBS) 
either within the proximal promoter region or else at enhancers, which functions to 
recruit and stabilize the PIC and drive transcription forward (37, 38). Indeed, the 
sequence variability of TFBS forms another layer of transcriptional regulation in 
themselves. For instance, many transcription factors form heterodimers and/or 
homodimers, with the precise combination of subunits a key factor in the TF’s binding 
specificity and regulatory output (37, 39). Furthermore, variations in the sequence may 
result in stronger or weaker interactions with TF’s, and may also direct a preference for 
particular dimerization partners over others (37, 39). One example of this is the NF-κB 
family of TFs. 
1.5 The NF-κB family 
The NF-κB family is a key player in controlling both innate and adaptive immune 
responses and NF-κB activity is required for lymphocyte survival and activation, as well 
as for mounting normal immune responses (40, 41). NF-κB proteins are constitutively 
present in the cytoplasm in association with proteins that are known as inhibitors of NF-
κB (IκBs). After activation by one of a variety of signals, the IκB proteins become 
phosphorylated, ubiquitinylated and degraded by the proteasome. Freed from their 
association with IκB, NF-κB proteins are able to translocate to the nucleus and bind their 
respective DNA binding sites to activate or repress the transcription of a vast array of 
14 
 
inflammatory genes, including cytokines, chemokines and a variety of antimicrobial 
peptides (42, 43). The constitutive activation of NF-κB pathways is often associated with 
inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, 
multiple sclerosis (MS) and asthma.  
Together, the NF-κB family of proteins consists of five members: NF-κB1 (p50), NF-
κB2 (p52), RelA (p65), RelB and cRel; each member may form a homodimer or a 
heterodimer with any other member, and these dimers in turn have differential abilities to 
regulate gene transcription (44). These proteins have a structurally conserved amino-
terminal 300-amino-acid region, which contains the dimerization, nuclear-localization 
and DNA-binding domains (Fig.1.3). The c-REL, RELB and p65 proteins also have a 
carboxy-terminal non-homologous transactivation domain, which strongly activates 
transcription from NF-κB-binding sites in target genes (41, 43).  The main activated form 
of NF-κB is a heterodimer of the p65 subunit associated with either a p50 or p52 subunit. 
The p50 and p52 proteins are generated by proteolytic cleavage of precursor p105 and 
p100 proteins, respectively. Converse to the main dimers containing p65, p50 and p52 
homodimers lack the transactivation domain, but still bind to NF-κB consensus sites in 
DNA and have been documented as repressing the transcription of some genes linked 
with inflammation (44-46). This function has been ascribed to the resolution phase of 
inflammation, in which it is important to suppress potentially toxic inflammatory factors 
(such as those released by neutrophils and eosinophils) in order to minimize damage to 
surrounding tissues (45). The precursor protein to the p50 subunit, p105, is especially 
interesting because it serves as both a NF-κB subunit precursor and an IκB protein (43).  
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With respect to the transcriptional functionality of NF-κB, The activation and nuclear 
translocation of classical NF-kB dimers (mostly p50-p65) is associated with increased 
transcription of genes encoding chemokines, cytokines, adhesion molecules [intercellular 
adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and 
endothelial – leukocyte adhesion molecule 1 (ELAM)], enzymes that produce secondary 
inflammatory mediators and inhibitors of apoptosis (42, 44). These molecules are 
important components of the innate immune response to invading microorganisms and 
are required for migration of inflammatory and phagocytic cells such as macrophages and 
nuetrophils to tissues where NF-kB has been activated in response to infection or injury. 
1.6 The peptidylarginine deiminase family 
Peptidylarginine deiminase (PAD) enzymes catalyze the conversion of arginine residues 
to citrulline residues in proteins (Fig. 1.4). Citrulline is a nonstandard amino acid, as it is 
not incorporated into proteins during translation and published reports that citrulline 
residues occur in proteins date as far back as 1939 (47).  To date, five family members of 
PAD have been identified in humans. These are: PAD1, PAD2, PAD3, PAD4 and PAD6 
(PAD6 does not appear to be active; (48, 49)). All these enzymes rely strongly on the 
presence of calcium ions for activity (Fig. 1.4) and are unable to convert free L-arginine 
into L-citrulline (a process catalyzed by nitric oxide synthase).  
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Figure 1.4 Citrullination of peptidylarginine by PAD. Schematic representation of the 
citrullination (deimination) reaction catalyzed by the PAD enzyme resulting in the net 
loss of positive charge. Adapted from Vossenaar et al. (49). 
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Although not much is known about the specificity of PAD towards protein substrates, 
studies with peptides indicate that certain amino acids flanking the arginine residue 
influence its susceptibility to citrullination by PAD. For instance, Arg flanked by two Pro 
residues is not citrullinated at all (50). The most noticeable difference between the 
isotypes is their tissue-specific expression. For example, PAD1 is expressed in epidermis 
and uterus, and has been shown to play a role in keratinocyte differentiation (49).  During 
terminal differentiation of keratinocytes, keratins (K1 and K10) and the keratin-
associated protein filaggrin are citrullinated and it is believed that the flexibility of the 
keratin cytoskeleton is reduced upon citrullination, stimulating the cornification of the 
epidermis (49, 51). Similar to PAD1, PAD3 is found mainly associated with the 
epidermis and in particular is localized in the inner root sheath cells of hair follicles (49). 
PAD2 is the most widely expressed of the family and while it can mainly be found in 
skeletal muscle, it is also expressed in brain (in particular the hypothalamus), spleen, and 
secretory glands as well as in macrophages (49).  
1.7 Biological function of PAD4 
PAD4 is the only member of the family that is located within the nucleus as it uniquely 
carries a nuclear localization sequence (NLS). Although PAD4 can be found broadly in 
white blood cells, it is mainly expressed in neutrophils where it has been shown to be 
essential to chromatin remodeling processes during neutrophil extracellular trap (NET) 
formation (49, 52, 53). More broadly however, PAD4 has gained increasing attention 
because of the unique role it plays in regulating immune function, gene transcription, as 
well as in maintaining the pluripotency of stem cells.  
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Within the inflammatory process, PAD4 plays an important role regulating the function 
of neutrophils. In response to a stimulus (e.g. lipopolysaccharide or LPS), a subset of 
neutrophils will undergo NET formation via the genome-wide citrullination of histones 
H1 and H3 (54, 55). Histone citrullination in cells undergoing NETosis leads to large-
scale chromatin decondensation, which initiates the expulsion of DNA from the cell to 
form net-like structures that can “trap” invading bacteria. However, while NETosis is a 
defense mechanism against invading organisms, its pro-inflammatory nature often links it 
to a variety of inflammatory disorders. For instance, in chronic autoimmune diseases, this 
process is aberrantly upregulated and likely plays an important role in the etiology of RA, 
systemic lupus erythematosus, ulcerative colitis, atherosclerosis, and even cancer (56-58). 
In cancer, recent data indicate that aberrant NET formation promotes vascular 
inflammation, leading to thrombosis (58).  
Histone citrullination by PAD4 has also been demonstrated to regulate gene transcription. 
In particular, citrullination of histones H3 and H4 has been demonstrated to be associated 
with decreased expression of genes under the control of the estrogen and thyroid 
receptors (53, 59, 60). Moreover, it was shown that treatment of U2OS cells, an 
osteosarcoma cell line, with the pan-PAD inhibitor Cl-amidine leads to decreased PAD4 
activity that was associated with the increased expression of p53 as well as several p53-
dependent genes, including p21, PUMA, and OKL38 as well as induction of apoptosis 
(61, 62).  
More recently, an intriguing role for PAD4 as a mediator of pluripotency in stem cells 
has been under investigation. Whereas it was previously thought that PAD4 was only 
expressed in mature neutrophils and other myeloid cells, it has now been demonstrated 
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that PAD4 is expressed in mouse embryonic stem cells (ES), induced pluripotent stem 
cells (iPS), as well as the LSK (Lineage-, Sca-1+, c-kit+) hematopoietic stem cells (63, 
64). Christophorou et al. (63) showed that increased levels of citrullinated H3 are 
correlative with higher levels of the pluripotency genes Klf2, Tcl1, Tcfap2c, and Kit. To 
further demonstrate that PAD4 activity is required to generate pluripotent stem cells, the 
authors treated mouse ES cells with the PAD inhibitor Cl-amidine and showed that 
decreased histone H3 citrullination was correlated with decreased expression of Nanog, 
Tcl1, and Klf5. Further verifying the importance of PAD4 in maintaining pluripotency, 
Cl-amidine treatment also increased the expression of several differentiation genes, 
including Epha1, Prickle1, and Wnt8a. These data are in agreement with findings 
published by Nakashima et al. (64) which showed that PAD4 regulates multipotency by 
controlling expression of c-kit. In total, these data suggest an exciting new avenue in the 
study of PAD4 and its function outside the immune response. 
1.9 PAD4, citrullination, and rheumatoid arthritis 
PAD4 has for some time been investigated for a role in RA pathogenesis (65). PAD4 is 
located on chromosome 1p36, and has been shown to be essential for NET formation 
(66). However, a serological examination of RA patients quickly reveals why PAD4 is 
being widely targeted as a factor in disease pathogenesis. As discussed above, a family of 
autoantibodies directed against proteins containing citrulline – termed anti-citrullinated 
protein antibodies (ACPAs) – can be found in high titers and with high specificity in the 
synovia of RA patients (67, 68). Some of these include anti-filaggrin autoantibody 
(AFA), anti-keratin antibody (AKA), anti-pernicular factor (APF), and anti-cyclic 
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citrullinated peptide antibody (anti-CCP) (68, 69). Indeed, diagnostic tests for ACPA’s 
show >97% specificity and sensitivity of at least 82% (19, 67), and have even been 
shown to be predictive of disease onset and severity (70). These characteristics of ACPAs 
have led to their wide use in diagnostic laboratories in testing for RA (19).  
The association between citrullinated proteins and onset of RA has stimulated great 
interest in the PAD enzymes, particularly PAD4. Studies in recent years have established 
that PAD4 is present in high levels in RA synovia and is itself a target of autoantibodies 
(69, 71). Furthermore, a meta-analysis of RA patients in Japan, North America, and 
Europe has established a positive correlation between polymorphisms in the PAD4 gene 
and RA incidence (72). Intriguingly, a recently published pan-PAD inhibitor, Cl-amidine, 
was used to treat mice with collagen-induced arthritis, inducing a ~50% reduction in 
disease activity (73).  
1.10 Hypothesis 
While much work has focused on PAD4 and its role in RA pathogenesis, little has been 
done to find out how PAD4 is transcriptionally regulated. The purpose of this study was 
therefore to determine how transcription of the PAD4 gene is regulated in the human 
myeloid lineage. Since it has been demonstrated to be a central mediator of the immune 
innate and adaptive immune responses, and since PAD4 has been shown to be essential to 
the functionality of neutrophils in the context of acute inflammation, it was hypothesized 
that NF-κB is an activator of PAD4 transcription during inflammation in RA 
pathogenesis. 
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Chapter 2: Materials and Methods 
2.1 Cell culture 
The human HL-60 cell line (American Type Culture Collection [ATCC], Manassas, VA) 
was cultured in media consisting of Iscove’s Modified Dulbecco’s Medium (IMDM) with 
4.5g/L glucose, HEPES buffer, and L-glutamine (Lonza, Shawinigan, QC) supplemented 
with 10% charcoal stripped fetal bovine serum (Wisent, St. Bruno, QC), penicillin (100 
U/mL)/ streptomycin (100 µg/mL)/ L-glutamine (.292 mg/mL) stock combination 
(Mediatech, Manassas, VA), and 5x10-5 M β-2-mercaptoethanol (Sigma-Aldrich, St. 
Louis, MO). The murine WEHI-3B and human THP1 cell lines (ATCC) were cultured in 
media consisting of RPMI-1640 medium with L-glutamine (Lonza) supplemented with 
10% fetal bovine serum (Wisent), penicillin (100 U/mL)/ streptomycin (100 µg/mL)/ L-
glutamine (.292 mg/mL) combination (Mediatech), and 5x10-5 M β-2-mercaptoethanol 
(Sigma-Aldrich).  
2.2 LPS stimulation 
Cultured human HL-60 cells were harvested and plated at 500,000 cells/well and 
incubated at 37°C for 24 h. The cells were then stimulated with LPS (Invitrogen) at a 
concentration of 1 µg/mL then incubated for 48h. Cultured murine WEHI-3B cells were 
harvested and plated at 500,000 cells/well in a 6-well plate and incubated at 37°C for 24 
h. The cells were then stimulated with LPS (Invitrogen) at a concentration of 400 ng/mL 
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and incubated for 72h. Total RNA was isolated and real time RT-qPCR was used to 
measure levels of PAD4 mRNA.  
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Table 2.1: PCR and RT-qPCR primer sequences 
Primer Name Sequence 
1 Murine PADI4 Real-Time PCR 5ʼ 
Primer 
5ʼ-TCTTTGTGGGTCACGTGGATGAGT-3ʼ 
2 Murine PADI4 Real-Time PCR 3ʼ 
Primer 
5ʼ-AGCTCCTGGAACAGCTGATAGCAA-3ʼ 
3 Murine GAPDH Real-Time PCR 5ʼ 
Primer 
5ʼ-GAACATCATCCCTGCATCCA-3ʼ 
4 Murine GAPDH Real-Time PCR 3ʼ 
Primer 
5ʼ-CCAGTGAGCTTCCCGTTCA-3ʼ 
5 TNF-α Real-Time PCR 5ʼ Primer 5ʼ-ATGAGCGAAAGCATGATCCGC-3ʼ 
6 TNF-α Real-Time PCR 3ʼ Primer 5ʼ-GTCTGGGCCATAGAACTGATGAGA-3ʼ 
7 Murine PADI4 Conserved Region 5ʼ 
Primer 
5ʼ-CTTTGATGTGGAGCCAAAGGAGACCC-3ʼ 
8 Murine PADI4 Conserved Region 3ʼ 
Primer 
5ʼ-GCTTATCTCTCTAGCAGATCTCTTGC-3ʼ 
9 PADI4 Promoter 5ʼ Primer 5ʼ-TAAGTGTGCTTGGGCAAGATGTGC-3ʼ 
10 PADI4 Promoter 3ʼ Primer with 
HindIII 
5ʼ-GAAGCTTCCTTGCTCGCTCGGTCAGC-3ʼ 
11 Murine PADI4 NFκB Mutation 5ʼ 
Primer 
5ʼ-GGAACCAGCCCAGCCGCTTCCTGCTGCC-3ʼ 
12 Murine PADI4 NFκB Mutation 3ʼ 
Primer 
5ʼ-GGCAGCAGGAAGCGGCTGGGCTGGTTCC-3ʼ 
13 Human PAD4 Promoter 5ʼ 5ʼ-ACTGTGGGCATGAGGACCAGGACC-3ʼ 
14 Human PAD4 Promoter 3ʼ 5ʼ-AAAGCTTCGTCGGGCTAGCTCGTCCC-3ʼ 
15 Human PAD4 NFκB Mutation 5ʼ  5ʼ-GATATAAAGGAACCAGCCCAGCCGCTTCCTACAGCCAGAGGGAC-3ʼ 
16 Human PAD4 NFκB Mutation 3ʼ 5ʼ-GTCCCTCTGGCTGTAGGAAGCGGCTGGGCTGGTTCCTTTATATC-3ʼ 
17 Human PAD4 Real-Time PCR 5ʼ 5ʼ-AGGAGGTGTACGCGTGCAGTATTT-3ʼ 
18 Human PAD4 Real-Time PCR 3ʼ 5ʼ-ATCCTGCATCCACTGGTCATCCAT-3ʼ 
19 Human GAPDH Real-Time PCR 5ʼ 5ʼ-CATGTTCGTCATGGGTGTGAACCA-3ʼ 
20 Human GAPDH Real-Time PCR 3ʼ 5ʼ-AGTGATGGCATGGACTGTGGTCAT-3ʼ 
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2.3 TNF-α stimulation 
Cultured cells were passaged into flasks containing 10 mL of pre-warmed medium two 
days before the treatment. The cells were passaged again into two flasks prior to 
treatment to a final concentration of 1 x 106 cells/mL. TNF-α (eBioscience, San Diego, 
CA) was then added for a final concentration of 1.7 x 10-4 µg/mL to one flask and both 
flasks were incubated for 1 h at 37°C. Total RNA was isolated and real time qPCR was 
used to measure the levels of PAD4 mRNA. 
2.4 Retinoic acid stimulation 
Cultured cells were passaged into flasks containing 10 mL of pre-warmed medium two 
days before the treatment. The cells were passaged again into two flasks prior to 
treatment to a final concentration of 3 x 106 cells/mL. The cells were then stimulated with 
retinoic acid (Sigma-Aldrich) dissolved in 95% ethanol. 10 µL of 3 µg/µL retinoic acid 
were added to one flask and 10 µL of 95% ethanol were added to the second. Both flasks 
were incubated at 37°C for 72 h. Total RNA was isolated and real time Q-PCR was used 
to measure the levels of PAD4 mRNA 
2.5 Bioinformatic analysis 
The sequence of the upstream region of the human PAD4 gene was obtained from the 
Ensembl database. Potential transcription factor binding sites were determined using the 
position-weight-matrices present in MatInspector (Genomatix, Munich, Germany).  
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2.6 RNA analysis 
Total RNA was isolated from cells using the RNA-Bee Isolation Kit (Tel-Test, 
Friendswood, TX). The iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA) was used to 
synthesize cDNA from 1µg of the extracted RNA. Real time PCR was performed using 
the iQ SYBR Green Supermix Kit (Bio-Rad) and analyses were done using a Rotor-Gene 
6000 (Corbett Life Science, San Fransisco, CA). Murine PAD4 transcript levels were 
measured and normalized in real time PCR analyses to murine GAPDH.  Human PAD4 
transcript levels were measured and normalized in q-PCR analyses to human GAPDH. 
Gene expression analysis was done using REST 2009 Software via the comparative 
threshold cycle method (Technical University of Munich, Munich, Germany).  
2.7 Plasmid construction 
In total, two sets of three reporter plasmids were constructed: pGL3+NF-κB FWD, 
pGL3-Basic+NF-κB REV, and pGL3+NF-κB MUT. The first two constructs contained 
the predicted PAD4 promoter in the forward and reverse directions, respectively.  To 
obtain these first two constructs, the conserved region of the PAD4 promoter was PCR 
amplified from C57BL/6 mouse DNA or from human HL-60 DNA. The PCR product 
was cloned using the StrataClone PCR Cloning Kit and cloned (Agilent Technologies, La 
Jolla, CA). Clones containing the target insert in the forward and reverse orientations 
were isolated to obtain the pGL3+NF-κB FWD and pGL3+NF-κB REV constructs, 
respectively. To obtain the pGL3+NF-κB MUT construct, the pGL3+NF-κB FWD 
construct was mutated using the QuikChange XL Site-Directed Mutagenesis Kit (Agilent 
Technologies). Before use, all three plasmid constructs were transformed into DH5α cells 
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and transfection-quality DNA was made using the QIAGEN Plasmid MAXI Kit 
(QIAGEN). 
2.8 Transient transfection analysis  
For each transfection, 5 x 106 cells were transfected with 10 µg of luciferase reporter 
plasmid and 0.5 µg of pRL-TK (Promega, Madison, WI). After a 10 minute incubation, 
the cells were electroporated at 220 V and 950 µF using a GenePulser II with Capacitance 
Extender Plus (Bio-Rad). The cells were incubated for 24 h at 37°C following another 10 
minute incubation at room temperature. Luciferase assays were performed using the 
Dual-Luciferase Reporter Assay System (Promega). The production of light was 
measured with a Lumat LB 9507 luminometer (Berthold Technologies, Oak Ridge, TN).  
2.9 Chromatin ImmunoPrecipitation (ChIP) 
HL-60 cells treated (or not) with TNF-α at 1.7 x 10-4 µg/mL were treated with 1% 
formaldehyde for 10 min at room temperature. Cross-linking was terminated with 125 
mM glycine. The cells were lysed in lysis buffer (50 mM Tris-HCl [pH 8.1], 10 mM 
EDTA, 1% SDS) containing Halt™ protease inhibitor mixture (Thermo Scientific). 
Chromatin solutions were sonicated to yield DNA fragments in the range 300–700 bp 
using a Bioruptor 300 waterbath sonicator (Diagenode, Sparta, NJ). Sonicated chromatin 
was incubated with rabbit polyclonal anti-human p50 or anti-human p65 antibodies 
(Abcam, Cambridge, MA) conjugated to protein G DynaBeads (Invitrogen, Burlington, 
Ontario, Canada) overnight at 4°C. As a control, sonicated chromatin was incubated with 
rabbit polyclonal IgG (Abcam) conjugated to protein G DynaBeads. Magnetic bead-
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bound complexes were enriched using a Dynal magnetic particle concentrator 
(Invitrogen). Bound beads were washed once with low-salt wash buffer (0.1% SDS, 1% 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.0], 150 mM NaCl), once with high-
salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl [pH 8.0], 500 
mM NaCl), once with LiCl buffer (0.25 M LiCl, 1% Nonidet P-40, 1% Na-deoxycholate, 
1 mM EDTA, 10 mM Tris-HCl [pH 8.0]), and twice with Tris-EDTA buffer at pH 8. 
Immunocomplexes were eluted with elution buffer (1% SDS, 0.1 M NaHCO3). Cross-
links were reversed in a final volume of 300 µl, containing 200 mM NaCl, overnight at 
65°C. DNA was purified using a Wizard SV Gel and PCR purification Kit (Promega). 
Enrichment was measured using qPCR of DNA immunoprecipitated with anti-FLAG or 
mouse IgG, using primers indicated in Table 2.1. Fold enrichment was calculated using 
the comparative threshold cycle method. 
2.10 Statistical Analysis 
All data are reported as mean ± SD of the mean. Statistical significance of luciferase 
assay and ChIP results was determined using students t test. Statistical analysis of RT-
qPCR results was done using REST 2009 software (Technical University of Munich). 
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Chapter 3: Results 
3.1 Identification of the PAD4 promoter 
Previous work in our laboratory was done to determine transcription start sites of the 
murine PAD4 gene (74). Analyses done using RNA obtained from murine WEHI-3B 
cells revealed possible transcription starts sites at -52 and -55 relative to the translation 
start site (74). Furthermore, previous work done in our lab showed evidence that the 
transcription start sites identified in the PAD4 gene were downstream of an active 
promoter (74). To test this region in human cells, the putative PAD4 promoter was 
analyzed for conserved regions by comparing the DNA sequences of the PAD4 locus 
from humans and six other species (Fig. 3.1). Regions that were highly conserved 
between species suggested that those regions represent functionally important regulatory 
elements (75, 76). A ClustalW alignment revealed several regions within 200 bp of the 
translation site that shared a high degree of sequence identity (Fig. 3.1), suggesting that 
this region may function as the PAD4 promoter.  Using the weight matrices available in 
MatInspector (Genomatix) which identify potential transcription factor binding sites 
based on known DNA binding patterns as well as biological function, four potential 
transcription factor binding sites in the PAD4 promoter were located: Kruppel like 
transcription factor, vertebrate TATA binding protein, NF-κB and ETS1 (Fig. 3.1).  
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Figure 3.1 Potential transcription factor binding sites identified within the conserved 
region of the PAD4 promoter. A region approximately 400 bp upstream of the PAD4 
ATG start codon contains two major conserved sequences and 150 conserved 
nucleotides.  A ClustalW alignment of the PAD4 promoter sequences from H. sapiens 
(human), M. musculus (mouse), R. norvegicus (rat), E. ferus (horse), L. africana 
(elephant), C. familiaris (dog), and S. scrofa (pig) is shown with the conserved sequences 
boxed. Bioinformatic analysis predicted binding sites for the transcription factors NF-κB, 
TATA-ETS-like, AP-1, KLF-6 as well as SP1. 
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3.2 PAD4 is inducible in human HL-60 cells 
Before performing experiments based on PAD4 expression, it was necessary to identify a 
human cell line that could express PAD4. It was previously reported that HL-60 cells can 
be induced with retinoic acid to express PAD4 (77), and we elected to repeat this. To that 
end, we stimulated cultured HL-60 cells with 3 µg/µL retinoic acid then extracted total 
RNA. Afterwards, cDNA was synthesized and real time qPCR was performed to analyze 
differences in PAD4 expression between retinoic acid-treated cells and control cells. This 
experiment was repeated three times and there was an average 2.3 fold increase of PAD4 
transcripts in HL-60 cells treated with retinoic acid relative to untreated cells (Fig. 3.2). 
These results demonstrate that HL-60 express PAD4 that is further inducible with retinoic 
acid. 
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Figure 3.2  PAD4 is inducible in HL-60 cells treated with retinoic acid. HL-60 cells in 
two culture flasks were treated with retinoic acid or an equal volume of 95% ethanol. 
Shown are the mean transcript levels ± S.D. from three independent triplicate 
experiments. There was a 2.3-fold increase in PAD4 transcript levels in treated cells. 
Asterisk indicates significant difference (p < 0.05) as measured by a  paired one-tailed 
students t-test. 
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3.3 The PAD4 promoter contains a potential NF-κB binding 
site 
NF-κB is a multifunctional transcription factor that participates in the regulation of the 
immune response and inflammation that has also been implicated in the development of 
autoimmune diseases. Since our bioinformatics analysis predicted the presence of a NF-
κB binding site in the PAD4 promoter, we elected to test whether NF-κB could be 
important in the regulation of PAD4 – itself an important mediator of innate immunity 
(40, 42, 52, 78).  
NF-κB family members have been shown to interact with a DNA core motif containing 
the consensus RGGRNNHHYYB (79-81). To test the activity of the predicted NF-κB site 
in the PAD4 promoter dual luciferase assays were carried out with various constructs. In 
brief, three reporter vectors were constructed (See 2.7-2.8). The first construct encoded 
the predicted NF-κB site in the forward orientation (FWD) directly upstream of the 
firefly luciferace gene, the second contained the predicted NF-κB site in the reverse 
orientation (REV) directly upstream of the firefly luciferace gene, and for the third 
construct site directed mutagenesis was used to convert the second and third guanosine 
residues into cytosines – a change expected to prevent NF- κB binding (Fig. 3.3B). 
Constructs containing the PAD4 wildtype or mutated human NF-κB site were transfected 
into human and murine cells. The human PAD4 promoter with a mutated NF-κB site 
displayed significantly lower biological activity (P <0.05) than the wild-type when 
transfected into murine WEHI-3B cells (Fig. 3.4). Interestingly however, reporter vectors 
containing the human PAD4 promoter with mutated NF-κB binding site transfected into 
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human HL-60 and THP-1 cells showed significantly greater activity than the wild-type 
(Fig. 3.5A and B; P <0.05). To test whether mutating the murine PAD4 promoter would 
have the same effect, constructs containing the murine PAD4 promoter were transfected 
into human HL-60 cells (Fig. 3.6). Mutation of the potential NF-κB binding site in the 
murine promoter did not cause a significant change in luciferase activity relative to wild-
type (Fig. 3.6). 
To further test the importance of the NF-κB binding site in the the human promoter 
relative to other upstream TFBS, we elected to conduct a deletion analysis in which 
promoter vectors containing varying lengths of the PAD4 promoter were transfected into 
human HL-60 cells. HL-60 cells transfected with constructs containing only the NF-κB 
binding site as well as the transcription start site (TSS) showed a modest but significant 
increase in luciferase activity relative to cells transfected with constructs containing only 
the TSS (Fig. 3.7).  These results suggest that the NF-κB site in the human PAD4 
promoter is functional and may act as an activating or a repressive element in murine and 
human cells, respectively.   
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Figure 3.3 Overview of the pGL3-basic luciferase reporter plasmids. (A) The PAD4 
promoter region inserted into the vector contains the potential NF-κB binding site. Three 
constructs were made to test the site. One containing the PAD4 promoter region in the 
forward orientation, another in the reverse, and the third with the PAD4 promoter region 
in the forward orientation with a mutation in the putative NF-κB binding site. (B) 
Alignment depicting the mutation of the NF-κB binding site, with the second and third 
guanosines mutated to cytosines. 
BA
35 
 
Figure 3.4 A predicted NF-κB site regulates PAD4 transcription in murine WEHI-3B 
cells. Three constructs were made to test the site; one containing the murine PAD4 
promoter region in the forward orientation (FWD), another in the reverse (REV), and the 
third with the PAD4 promoter region in the forward orientation with a mutation in the 
putative NF-κB binding site (MUT). The positive control (+) was a construct containing 
the viral SV40 promoter upstream of the luciferase gene. The negative control (-) was a 
promoter-less construct. Mutation of the human NF-κB results in decreased human 
promoter activity in murine WEHI-3B cells. Results shown are from three biological 
experiments performed in technical duplicate. Paired, one-tailed student’s t test was used 
to compare luciferase activity from the FWD construct to that of the MUT construct. 
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Figure 3.5 A predicted NF-κB site regulates PAD4 transcription in human myeloid cells. 
Three constructs were made to test the site; one containing the human PAD4 promoter 
region in the forward orientation (FWD), another in the reverse (REV), and the third with 
the PAD4 promoter region in the forward orientation with a mutation in the putative NF-
κB binding site (MUT). The positive control (+) was a construct containing the viral 
SV40 promoter upstream of the luciferase gene. The negative control (-) was a promoter-
less construct (A) Mutation of the NF-κB binding site in the human PAD4 promoter 
significantly increases promoter activity in human HL-60 cells. Shown is the relative fold 
difference in biological activity of each reporter normalized to the pGL3-basic promoter-
less plasmid. Results are an average of three biological experiments performed in 
duplicate. (B) Mutation of the NF-κB binding site significantly increased human PAD4 
promoter activity in human THP-1 cells. Shown are the results of three biological 
replicates performed in duplicate. Paired, one-tailed student’s t test was used to compare 
luciferase activity from the FWD construct to that of the MUT construct. 
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Figure 3.6 A predicted NF-κB site in the murine PAD4 promoter does not affect 
transcription in human cells. Three constructs were made to test the site; one containing 
the murine PAD4 promoter region in the forward orientation (FWD), another in the 
reverse (REV), and the third with the PAD4 promoter region in the forward orientation 
with a mutation in the putative NF-κB binding site (MUT). The positive control (+) was a 
construct containing the viral SV40 promoter upstream of the luciferase gene. The 
negative control (-) was a promoter-less construct Mutation of the murine NF-κB binding 
site has no effect on promoter activity in human HL-60 cells. Shown is the relative fold 
difference in biological activity of each reporter normalized to the pGL3-basic promoter-
less plasmid. A paired, one-tailed student’s t test was used to compare luciferase activity 
from the FWD construct to that of the MUT construct and there was not a significant 
difference between the two. Results are an average of three biological replicates 
performed in duplicate.  
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Figure 3.7 The predicted NF-κB site in the human PAD4 promoter increases luciferase 
activity. Inclusion of the NF-κB binding site into the luciferase construct containing the 
PAD4 TSS (TSS+NF-κB) causes a significant increase in luciferase activity. Shown is 
the relative fold difference in biological activity of each reporter normalized to the pGL3-
basic promoter-less plasmid. Results are an average of three biological replicates 
performed in duplicate. A paired, one-tailed student’s t test was used to compare 
luciferase activity from the TSS construct to that of the TSS+NFkB construct. 
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3.4 Inflammatory stimuli regulate PAD4 expression 
Since the luciferase results suggested the presence of a functional NF-κB binding site in 
the human and murine PAD4 promoters (Fig. 3.4-3.7), we elected to test the effect of NF-
κB activation on endogenous PAD4 transcript levels. TNF-α or LPS – known activators 
of the NF-κB pathway – were used to stimulate human HL-60 and WEHI-3B cells (82, 
83). Since both TNF-α and IL8 are markers of NF-κB activation, they were used as 
positive controls in these experiments (84). WEHI-3B cells treated with TNF-α displayed 
a 5.9-fold increase in TNF-α transcript levels and a 3-fold increase in PAD4 transcript 
levels (Fig. 3.8). Human HL-60 cells treated with LPS did not show a significant change 
in PAD4 or IL8 transcript levels (Fig. 3.9A). Gene expression analysis was done using 
REST 2009 Software via the comparative threshold cycle method (Technical University 
of Munich,). This result suggests that human HL-60 cells grown in culture are not 
responsive to LPS treatment. Finally, HL-60 cells treated with TNF-α showed a 
significant 2.7-fold increase in IL8 transcript levels –– along with a significant 1.3 fold 
decrease in PAD4 transcript levels (Fig. 3.9B; P <0.05). These results were consistent 
with our previous findings and suggest that NF-κB may function as a transcriptional 
repressor of PAD4 in humans while acting as an activator in murine cells.  
 
 
 
41 
 
Figure 3.8 Induction of NF-κB upregulates PAD4 in mouse WEHI-3B cells. Fold 
induction of GAPDH, PAD4 and TNF-α transcript levels in murine WEHI-3B cells 
treated with 1.7 x 10-4 µg/mL TNF-α. TNF-α transcript levels increased 5.88 fold while 
PAD4 transcript levels increased 3.2 fold in treated cells. Gene expression analysis was 
done using REST 2009 Software via the comparative threshold cycle method (Technical 
University of Munich, Munich, Germany). 
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Figure 3.9 Induction of NF-κB downregulates PAD4 in human myeloid cells (A) Fold 
induction of GAPDH, PAD4 and TNF-α transcript levels in human HL-60 cells treated 
with LPS. Cells were treated with 400 ng/ml LPS and incubated for 72 hours. There was 
not a significant change in PAD4 or IL8 transcript levels. (B) Fold induction of GAPDH, 
PAD4 and TNF-α transcript levels in human HL-60 cells treated or not with TNF-α. 
Shown are the mean transcript levels ± S.D. from three experiments performed in 
triplicate. IL8 transcript levels increased 2.67 fold whereas PAD4 transcript levels were 
reduced 0.71 fold in treated cells. * p<0.05 
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3.5 P50 binds to the PAD4 promoter  
Finally, we investigated the potential role of NF-κB family members p50 and p65 in 
binding directly to the PAD4 promoter. P50-p65 heterodimers form the “classical” NF-
κB transcriptional activator responsible for most canonical NF-κB-mediated expression 
of inflammatory response genes (45, 85, 86). Conversely, p50 homodimers have been 
demonstrated to repress several different inflammatory genes controlled by NF-κB in a 
manner consistent with the resolution phase of inflammation (45, 46). Both p65-p50 
heterodimers and p50 homodimers can be activated via the canonical pathway involving 
activation of the TNF receptor (TNFR) by TNF- α (44, 45). Therefore, we hypothesized 
that inducing the NF-κB pathway via TNFR stimulation would lead to production of the 
active forms of both p65-p50 heterodimers (the activating heterodimer) as well as 
repressive p50 homodimers. To determine if these NF-κB subunits bind the PAD4 
promoter, we performed chromatin immunoprecipitation (ChIP) analysis. Chromatin 
prepared from HL-60 cells treated or not with TNF-α was immunoprecipitated with either 
rabbit polyclonal anti-human p50 or anti-human p65 antibodies and rabbit polyclonal IgG 
to control for non-specific binding. qPCR was used to determine the relative amount of 
immunoprecipitated DNA from the PAD4 promoter region, the IL8 promoter region with 
which p50 and p65 is known to interact with as a positive control, and the negative 
control C4ORF11, a gene expressed at low levels and with no known binding to NF-κB  
(Fig. 3.11; (84, 87)).  ChIP analysis confirmed that p65 was highly enriched at the IL8 
promoter, but not significantly enriched at the PAD4 promoter upon TNF-α stimulation 
(Fig. 3.10A; B). However, p50 enrichment at the PAD4 promoter was significantly 
greater in treated cells than untreated (Fig. 3.11A, B; p=0.017). Taken together, these 
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data are consistent with the possibility that p50 homodimers of NF-κB directly interact 
with the human PAD4 promoter and act to functionally repress PAD4 during 
inflammation. 
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Figure 3.10 The p65 subunit of NF-κB does not interact directly with the human PAD4 
promoter upon TNF-α stimulation. Human HL-60 cells were treated or not with TNF-α 
for one hour before chromatin immunoprecipitation (ChIP) analysis to examine p65 
binding to the NF-κB site in the PAD4 promoter. Real time quantitative PCR (RT-qPCR) 
was used to quantify fragments of DNA immunoprecipitated with rabbit polyclonal anti-
human p65 and rabbit polyclonal IgG (control). (A) Representative figure from three 
anti-p65 ChIP experiments. Results are expressed as levels of DNA immunoprecipitated 
with anti-p65 IgG i.e. as a percentage of input DNA. Levels of p65 enrichment at the IL8 
promoter (positive control) were higher in treated cells than untreated. There was no 
change in levels of p65 enrichment at the C4ORF11 promoter in treated and untreated 
cells. + and - refer to TNF-α treatment. (B) Results of all p65 (n=3) ChIP experiments. 
Data is expressed as fold enrichment of DNA immunoprecipitated with anti-p65 IgG 
normalized to DNA immunoprecipitated with IgG. There was not a siginificant change in 
p65 enrichment at the PAD4 promoter in treated cells relative to untreated. Significance 
was measured using student’s t test.  
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Figure 3.11 The p50 subunit of NF-κB interacts directly with the human PAD4 promoter 
upon TNF-α stimulation. Human HL-60 cells were treated or not with TNF-α for one 
hour before chromatin immunoprecipitation (ChIP) analysis to examine p50 binding to 
the NF-κB site in the PAD4 promoter. Real time quantitative PCR (RT-qPCR) was used 
to quantify fragments of DNA immunoprecipitated with rabbit polyclonal anti-human 
p50 and rabbit polyclonal IgG (control). (A) Representative figure from seven anti-p50 
ChIP experiments. Results are expressed as levels of DNA immunoprecipitated with anti-
p50 IgG i.e. as a percentage of input DNA. Levels of p50 enrichment at the IL8 promoter 
(pos. control) were higher in treated cells than untreated. There was no change in levels 
of p50 enrichment at the C4ORF11 promoter in treated and untreated cells. + and - refer 
to TNF-α treatment. (B) Results of all p50 (n=7) ChIP experiments. Data is expressed as 
fold enrichment of DNA immunoprecipitated with anti-p50 IgG normalized to DNA 
immunoprecipitated with IgG. There was a siginificant increase in p50 enrichment at the 
PAD4 promoter in treated cells relative to untreated. Significance was measured using 
student’s t test.  
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Chapter 4: Discussion 
4.1 Overview 
Rheumatoid arthritis is an autoimmune disease whose etiology remains elusive because 
of the myriad environmental and genetic factors that have potential roles in its 
pathogenesis (22, 24). One of the potential genetic factors being considered for a role in 
RA is the gene encoding PAD4, an enzyme that catalyzes the post-translational 
modification of citrullination. PAD4 is particularly interesting because it is found in the 
rheumatoid synovial membrane, synovial fluid cells (for example, neutrophils), and 
extracellular synovial fluid (19, 88). Meta-analyses of Japanese, European and North 
American populations have established a correlation between polymorphisms in the 
PAD4 gene and RA incidence (72). A family of autoantibodies directed against proteins 
containing citrulline – termed anti-citrullinated protein antibodies (ACPAs) – can be 
found in high titers and with high specificity in the synovia of RA patients (67, 68). 
Finally, PAD4 has itself been found to be a target of antibodies in RA (71). The goal of 
this study was to determine how transcription of PAD4 gene is directed in the human 
myeloid lineage, and whether NFκB is an activator of PAD4 transcription. Over the 
course of my thesis, I characterized the human PAD4 promoter and demonstrated its 
activity. In turn, I analyzed both the human and murine PAD4 promoters for possible 
transcription factor binding sites, located a possible NF-κB site, and determined that the 
site was active.  I hypothesized that this NF-κB binding site could play a role in 
regulating PAD4 transcription. I tested this idea by using inflammatory stimuli to activate 
the NF-κB pathway in cultured cells, showing that inflammatory stimuli caused changes 
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in PAD4 transcription. Finally, I demonstrated that the NF-κB subunit p50 directly 
interacts with the PAD4 promoter independently of p65, suggesting that p50 homodimers 
act to suppress PAD4 transcription in the context of human inflammation. 
4.2 NF-κB may be important for transcriptional regulation of 
PAD4 
NF-κB is a particularly interesting candidate vis-a-vis rheumatoid arthritis because of the 
essential role it plays in human immunity. Indeed, several inflammatory diseases are 
characterized partly by activation of NF-κB including asthma, inflammatory bowel 
syndrome, atherosclerosis, and rheumatoid arthritis (89). Together, the NF-κB family of 
proteins consists of five members: NF-κB1 (p50), NF-κB2 (p52), RelA (p65), RelB and 
cRel; each member may form a homodimer or a heterodimer with any other member, and 
these dimers in turn have differential abilities to regulate gene transcription (44). In 
unstimulated cells, NF-κB is sequestered in the cytoplasm by IκB proteins. In turn, the 
IκB protein family consists of three functional groups: the typical IκB proteins IκBα, 
IκBβ and IκBε, all three of which are present in the cytoplasm of unstimulated cells and 
are degraded as a consequence of stimulation; the precursor proteins p100 and p105, 
which can be processed to form the NF-κB family members p52 and p50, respectively; 
and finally the atypical IκB proteins including IκBζ, BCL-3 (B-cell lymphoma 3) and 
IκBN, all of which are not normally expressed in the cytoplasm, but are expressed in 
response to activation and act to modulate transcription thereafter.  
In response to activation, IκBα undergoes ubiquitin-mediated proteasomal degradation 
that results in the release of the bound NF-κB dimers. The cytoplasmic NF-κB (most 
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often in the form of p65-p50 heterodimers) then translocates to the nucleus and drives 
gene expression. NF-κB dimers are involved in both the activation and repression of a 
host of different genes involved in the immune response. The regulatory mechanisms 
regulating the activating or repressive function of NF-κB are complex and often involve 
substantial crosstalk between different pathways in context and cell-specific ways (90, 
91). For instance, p50 and p52 homodimers have for some time been known to repress 
the transcription of some genes linked with inflammation (44, 45). However, this 
repression is often augmented by the presence of BCL-3, an atypical IκB family member, 
which is present in the nucleus and can either stabilize the repressive function of p50 
homodimers already bound to DNA or else it may bind the homodimer and confer 
transcriptional activation ability (92, 93). Furthermore, the inflammatory context in 
which the cell is present has been advanced as another factor in the nature of NF-κB 
function. For example, the repressive function of p50 and p52 homodimers has been 
ascribed to the resolution phase of inflammation, in which it is important to suppress 
potentially toxic inflammatory factors (such as those released by neutrophils and 
eosinophils) in order to minimize damage to surrounding tissues (45). Thus the activation 
or repressive function of NF-κB dimers can be ascribed not only to the particular 
combination of subunits, but also to the stage of inflammation the cell is in. 
Another factor in the function NF-κB is the physical sequence to which the transcription 
factor binds. While it was previously hypothesized that all NF-κB dimers bind a single 
consensus sequence, more recent data has emerged demonstrating that different dimers 
have slightly different sequence preferences (79, 94, 95). In particular, the GGAA motif 
has been shown to be most highly associated with p65 binding whereas p50 and p52 
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homodimers have less affinity for that motif and a higher preference for the motif 
GGGRY (R= purine, Y= pyrimidine) (79) – the motif present in the NF-κB site in the 
PAD4 promoter (Fig. 3.1). This observation is consistent with the results of our 
experiments that suggest that p50 preferentially binds the PAD4 promoter compared with 
p65 and that it may do so in the form of the repressive p50 homodimer (Fig. 3.9-3.11). 
The importance of the DNA sequence to which NF-κB is made even more clear by 
results in murine cells which indicate that, converse to the situation in the human cell 
lines, NF-κB may activate PAD4 transcription in murine WEHI-3B cells (Figs. 3.4 and 
3.8). This discrepancy may be explained by an insertion in the murine promoter that is 
not present in the human promoter approximately 300 bp upstream of the TSS (Fig. 3.1). 
In the murine promoter, this insertion is part of a larger sequence that includes the 
nucleotides GGGGGGTCCTG which falls within the consensus binding site for NF-κB 
(79-81, 96). Since this insertion is not present in the human promoter, no such binding 
site exists for the human PAD4 promoter. Thus it may be NF-κB plays a differential role 
in regulating the transcription of PAD4 in murine and human myeloid cells. 
The results of our study are consistent with the previously established role of PAD4 in 
the inflammatory response. We demonstrated that NF-κB (in the form of p50) binds the 
PAD4 promoter in human neutrophils, and correlates with repression of gene 
transcription thus providing a potential link between inflammation and the regulation of 
the PAD4 gene.  
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4.3 The potential role of PAD4 during chronic inflammation in 
rheumatoid arthritis 
The PAD4 enzyme has emerged as a potentially key participant in the pathogenesis of 
rheumatoid arthritis because of its importance to neutrophil function in innate immunity 
as well as its putative role in other autoimmune diseases. The PAD4 gene is located on 
chromosome 1p36, and genome wide associate studies as well as a subsequent meta-
analysis of these studies have demonstrated an association between polymorphisms in the 
PAD4 gene and RA (72, 97-99). Interestingly, a genome wide screen of multiplex RA 
families found that genetic regions contributing to RA risk overlapped with those 
contributing to other autoimmune diseases such as multiple sclerosis and systemic lupus 
erythematosus – a finding reflective of PAD4’s implicated role in those diseases because 
of its role in inflammation (52, 100).  
The PAD4 enzyme is located in the nuclei of neutrophils and has been shown to mediate 
citrullination of histones, a process that induces chromatin decondensation and, 
ultimately, NET formation (53, 101). NETosis is an effector mechanism of neutrophils 
unique from phagocytosis or apoptosis and involves the ejection of nuclear DNA 
decorated with a variety of modified nuclear and granular proteins that in turn ensnare 
extracellular bacteria and induce their death (10). NETs act as a mesh that traps 
microorganisms and facilitates their interaction with neutrophil-derived effector 
molecules, limiting the spread of pathogens (10). A number of studies have implicated 
NETs in the etiology of autoimmune conditions such as preeclampsia, Felty syndrome, 
SLE, multiple sclerosis, as well as RA (12, 13, 56, 102-105). In the context of RA, it has 
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been hypothesized that because of their ejection of intracellular (and citrullinated) 
contents to the extracellular space, NETs contribute to the generation of anti-citrullinated 
protein antibodies (ACPA), and may themselves also be targets of autoantibodies (56, 
106). Furthermore, neutrophils isolated from RA patients have been shown to display a 
heightened propensity towards spontaneous and LPS-induced NETosis, which was in part 
mediated by TNF and IL-17 and could be inhibited by blocking NADPH oxidase or 
PAD4 (56, 106). Indeed, chemical inhibition of PAD4 significantly reduces histone 
citrullination and NET formation, and neutrophils of mice lacking PAD4 are unable to 
decondense chromatin and produce NETs leading to increased susceptibility to bacterial 
infections (66, 101, 107). Intriguingly, inhibition of NF-κB has recently been documented 
to reduce NET formation, compatible with a role for NF-κB in the regulation of PAD4 
expression (108). 
4.4 Future directions 
Future directions of this work include further elucidation of the role NF-κB has in 
regulating PAD4 expression over the course of inflammation. Moreover, the 
identification of other regulatory sites within the PAD4 gene, such as other transcription 
factor binding sites, is an important objective. Finally, although in vitro models of cell 
manipulation can be useful, it would be advantageous to test the connection between 
inflammation and PAD4 expression in vivo using mice. More specifically, although our 
results indicate a differing role for NF-κB in the regulation of PAD4 in mouse and human 
cells, it would be useful to investigate the role of PAD4 in inflammation and NETosis in 
a mouse model of rheumatoid arthritis.  
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With respect to the role of NF-κB, one experiment that may be done to further clarify 
whether NF-κB regulates PAD4 expression is to activate HL-60 cells with TNF-α (as 
done previously) and treat immediately with the NF-κB inhibitor JSH-23 (109). 
Additionally, to test the relative importance of the NF-κB binding site in the PAD4 
promoter, it is important to construct luciferase reporter plasmids containing the 
identified potential binding sites for AP-1 and SP1 and compare to data for NF-κB. 
Finally, to test the ability of PAD4 to citrullinate targets in the extracellular environment, 
an experiment that can be done is to induce primary human neutrophils to undergo 
NETosis using PMA and measuring PAD4 activity in the extracellular environment.  
Our long-term goal is to understand the role played by PAD4 in rheumatoid arthritis in 
order to establish novel therapies and treatments for RA. While current treatments of RA 
aim to minimize the pain and inflammation caused by the disease, we have yet to develop 
measures that are adequate to the underlying auto-immunological cause. To that end, 
PAD4 has so far proven to be a plausible target for treatment; PAD inhibitors such as Cl-
amidine have been used to treat mice with collagen-induced arthritis with notable success 
and continue to be studied as possible therapeutic agents (73). 
4.5 Summary and conclusions 
We speculate that repression of PAD4 by NF-κB might be useful in the context of the 
resolution phase of inflammation, in which the activity of NETs must be checked in order 
to prevent chronic inflammation. Moreover, the negative regulation of PAD4 might serve 
to limit NET formation during the acute phase of inflammation, thus reducing “collateral 
damage” caused by excessive NET formation as well as limiting the release of 
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autoantigens including citrullinated proteins into the extracellular space. However, in 
patients with RA, it is conceivable that mutations in the PAD4 promoter results in 
lowered p50 binding and continued, unattenuated expression of PAD4 (Fig. 4.1). This is 
turn may contribute to hypercitrullination of histones in the nuclei of neutrophils, leading 
to excessive NET formation and finally resulting in a “runaway” immune response 
involving accumulation of citrullinated products in the synovium and the breaking of 
immune tolerance. 
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Figure 4.1 A possible mechanism for dysregulation of PAD4 expression. In unaffected 
persons, p50 homodimers may bind the PAD4 promoter during the resolution of 
inflammation, suppressing the formation of NETs. Persons susceptible to RA may have a 
mutation that prevents p50 binding and results in overexpression of PAD4. 
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If, as our results suggest, NFκB functions as a repressor of PAD4 expression in human 
immune cells, it is possible that in individuals unaffected by RA, an infection would 
begin in the inflammatory phase with the general activation of neutrophils and the release 
of NETs regulated by PAD4 (66). As inflammation moves into the resolution phase, NF-
κB dimers involved in immunosuppression predominate, and this would involve 
formation of p50 homodimers. Since the PAD4 promoter contains the NF-κB motif that 
is most preferred by p50 subunits (79), it might be preferentially bound by p50 
homodimers and its expression repressed, resulting in less NET formation and inhibition 
of neutrophil function in maintaining inflammation (Fi.g 4.1). In patients with RA, it is 
possible that a lack of p50 binding to the PAD4 promoter causes continued, unattenuated 
expression of PAD4, resulting in a “runaway” immune response involving accumulation 
of PAD4 in the synovium and breaking of immune tolerance (Fig.4.2). 
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Figure 4.2 Interplay between inflammation, NF-kB, and PAD4 expression (A) During 
the resolution phase of inflammation we hypothesize that NF-κB represses PAD4 
expression to reduce NET formation and thus “dial down” the inflammatory response, 
itself an activator of NF-κB. (B) Without the repression of PAD4, an uncontrolled 
positive loop would occur, leading to chronic inflammation. 
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